CalciMedica vs. Zelta
| Product | Rating | Most Used By | Product Summary | Starting Price |
|---|---|---|---|---|
 CalciMedica | N/A | N/A | CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr. Stauderman’s work includes the discovery of the role of STIM1, which works in… | N/A |
 Zelta | Score8 out of 10 | N/A | Zelta is a cloud-based unified clinical data management and acquisition platform with customizable modules, that can be tailored to the meet the needs of clinical trials and accelerate outcomes. | N/A |
| CalciMedica | Zelta | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Editions & Modules | No answers on this topic | No answers on this topic | ||||||||||||||
| Offerings |
| |||||||||||||||
| Entry-level Setup Fee | No setup fee | Optional | ||||||||||||||
| Additional Details | — | Subscription - For larger organizations and those who need a predictable budget. Most modules included without incurring additional fees. Eligible for volume discounts. Pay per use - For organizations that need flexibility without a long term contractual commitment. Transparent a la carte pricing, no minimums. Fees start when trial goes live. | ||||||||||||||
| More Pricing Information | ||||||||||||||||
| CalciMedica | Zelta | |
|---|---|---|
| Likelihood to Recommend | - | 8.0 |
| Likelihood to Renew | - | 9.1 |
| Usability | - | 8.0 |
| Availability | - | 8.2 |
| Performance | - | 7.3 |
| Support Rating | - | 9.0 |
| Implementation Rating | - | 8.2 |
| Configurability | - | 8.2 |
| Ease of integration | - | 7.3 |
| Product Scalability | - | 7.3 |
| Vendor post-sale | - | 7.3 |
| Vendor pre-sale | - | 7.3 |